Anti-CD25 for steroid-resistant liver cGVHD
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a treatment called anti-CD25 for people whose chronic graft-versus-host disease (cGVHD) affects the liver and hasn’t improved with steroids. The goal is to see if this treatment can help control the immune response without causing serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You have had a stem cell transplant from a donor.
- Your chronic GVHD is affecting your liver and has not gotten better with prednisone (a steroid).
- You have tried no more than 4 different treatments for GVHD before this one.
- You agree to receive the study drug, anti-CD25.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medications (belumosudil and ruxolitinib) together for chronic graft-versus-host disease (cGvHD)—a condition where transplanted immune cells attack your body—that did not improve with steroid treatment alone. The trial aims to help patients whose disease is resistant to standard steroids.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
This trial tests a combination of a steroid and a humanized antibody (called CD25 monoclonal antibody) as the first treatment for moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if this combination is safer and more effective than steroids alone.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.